If approved, we believe pemvidutide could offer an important option for obesity patients, including those with risk factors for cardiovascular disease. However, tolerability issues remain, as the trial led to one participant experiencing vomiting, and 4.1% of the patients in the drug cohort discontinuing treatment in the first 16 weeks, when compared to 2.1% in the placebo group
At this time, however, these conclusions are limited to speculation given the nature of a single case report
Toniolo A, Fadini GP, Tedesco S, et al
It is clearly multi-faceted and we believe this is from the additional overlay of the shift away from the athleisure category post-COVID and incremental competition flooding the market. At the same time, Boruchow said he is incrementally positive on intimates, dresses, denim and fashion apparel, with a focus on bottoms and other categories sensitive to sizing
conclusion Taurine and L-carnitine are best understood as complementary ingredients rather than interchangeable ones